FDA Approves New Low-Dose MRI Contrast Agent

The FDA has approved Bayer's Gadoquatrane, marketed as AMBELVIST®, for use as an MRI contrast agent. This new macrocyclic gadolinium-based agent offers significantly lower gadolinium exposure compared to existing options. It is approved for both adult and pediatric patients, providing enhanced visualization for various medical conditions.